

Company Overview

Global Innovator

Know Labs is an emerging developer of non-invasive medical diagnostics technology with a novel approach to blood glucose monitoring using radiofrequency (RF) dielectric spectroscopy.

Medical Device

Medical device with high level of accuracy, on the path to FDA clinical trials for clearance.

IP Leadership

#1 global IP holder in non-invasive blood glucose monitoring with 270+ patents issued, pending, and in-process worldwide, covering 100+ applications and creating a defensible moat surrounding its technology.

Affordable

Non-invasive solution with long-lasting, rechargeable sensor does not require costly, single-use disposables as in current, more invasive solutions.

The Know Labs Technology Platform

3D Data Improves Clinical Accuracy



Powerful

Safely sweeps through the full tissue stack to collect high-resolution voltage data at high speed, enabling a measurement of glucose and other analytes optical sensors are unable to achieve with fixed wavelengths.

100+ Potential Applications

Identifies and measures a range of organic and inorganic materials, with 100+ applications in health care and other industries.

Form Factor Agnostic

Integrated into a variety of wearable, mobile, or bench-top form factors.

Non-Invasive (Pain-Free)

Truly non-invasive. No needles or minimally invasive transmitters.

AI / ML

Proprietary machine learning algorithms manage and interpret large datasets to deliver accurate blood glucose values.

Radiofrequency Dielectric Spectroscopy

Proprietary radiofrequency (RF) sensor measures glucose levels using dielectric spectroscopy by rapidly scanning a large range of RF frequencies. It records voltage values detected at each frequency to quantify, with trade-secret machine learning algorithms, real-time continuous blood glucose levels.

KnowU™ Product Form Factors

Generation 1



- **On-the-go** form factor
- On-demand, non-invasive blood glucose value
- Computer mouse size

KnowU™



- **Wearable** form factor
- Continuous monitoring
- 86% smaller and 68% lighter than previous Generation



Know Labs' Continuous Glucose Monitoring device will connect to a smartphone App via Bluetooth.

Scientific Validation: Stability, Repeatability, Accuracy

	2021	2022	2023				Today
Study	Proof of Principle with Mayo Clinic	Exploratory Clinical Study	Proof of Concept Clinical Study	Technical Feasibility Study	New Algorithm Refinement Study	Data Preprocessing Techniques Study	Study Among PWD Using Venous Blood Comparator
Accuracy	Almost 100% <i>in vitro</i> accuracy.	Glucose, metabolized drugs, oxygen	MARD 19.3%	MARD 20.6%	MARD 12.9%	MARD 11.3%	MARD 11.1%
Number of Participants	na	2	1	5	5	13	10 (expanded dataset, n-30, completed in Feb, 2024)
Range Measured	na	normo	normo	normo	normo	normo	normo & hyper
Reference Observations	na	75	~383	~1,555	~1,555	~3,311	650 paired RF and reference BG values

Visit: knowlabs.co/research-and-development

Executive Team

Ron Erickson: Chairman & CEO
Pete Conley: CFO & SVP Intellectual Property
Jordyn Hujar: Chief of Staff
Leo Trautwein: Chief Commercial Officer
Steve Kent: Chief Product Officer
Jessica English: Chief Marketing Officer

Corporation

Headquarters: Seattle, WA
Cap structure: Post-IPO Equity
NYSE American: KNW
Market Cap: ~\$50M (May 2023)
Contact: ask@knowlabs.co
www.knowlabs.co

Know Labs' Technology is in development, and there is no assurance that the development will have a successful outcome. Past performance is not indicative of future results. There is no guarantee that any specific objective will be achieved.
 © Know Labs, Inc. 2024